Lixisenatide vs Tesofensine
Head-to-head comparison of Lixisenatide and Tesofensine for research applications. Both peptides are studied for various research applications, but they differ significantly in mechanism and evidence level.
Side-by-Side Comparison
| Attribute | Lixisenatide | Tesofensine |
|---|---|---|
| Category | Metabolic / GLP-1 Agonist | Weight Loss / Reuptake Inhibitor |
| Mechanism | Lixisenatide is a 44-amino-acid peptide that activates the GLP-1 receptor with high affinity. | Tesofensine inhibits the presynaptic reuptake of serotonin, norepinephrine, and dopamine, increasing synaptic concentrations of all three monoamines. |
| Evidence Rating | A — FDA Approved | C — Phase II–III Clinical Trials |
| Clinical Status | FDA-approved (Adlyxin for T2D, July 2016; Soliqua 100/33 combination, November 2016) | Phase 3 clinical trials (Saniona). Phase 2 completed with significant weight loss results. |
| Safety Profile | Common (>=5%): nausea (25%), vomiting (10%), headache (9%), diarrhea (8%); GI side effects are typically transient, most common during first 2-3 weeks of treatment | Phase 2 trials reported increased heart rate (5-8 bpm) and blood pressure elevation at higher doses; Common side effects: dry mouth, insomnia, constipation, nausea, diarrhea |
| Molecular Weight | ~4858.5 g/mol | ~397.5 g/mol |
| Half-Life | ~3 hours | N/A |
Overview
Lixisenatide and Tesofensine are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, and safety profiles to help researchers understand the key differences and overlaps.
Lixisenatide — Mechanism & Evidence
Lixisenatide is a once-daily GLP-1 receptor agonist (MW ~4858.5 g/mol) based on the exendin-4 scaffold, with a modified C-terminal tail containing six lysine residues. It is also marketed as Lyxumia outside the United States. Lixisenatide is available in a fixed-ratio combination with insulin glargine as Soliqua 100/33.
Key claims: Reduces HbA1c in type 2 diabetes; Potent reduction of postprandial glucose; Effective in combination with basal insulin.
Tesamorelin 10mg
10mg
Tesofensine — Mechanism & Evidence
Tesofensine is a triple monoamine reuptake inhibitor (serotonin, norepinephrine, dopamine) originally developed for Alzheimer's and Parkinson's disease. The compound was developed by NeuroSearch A/S and later licensed to Saniona, which is pursuing Phase 3 trials.
Key claims: Produces significant weight loss (~10% body weight); Suppresses appetite and reduces caloric intake; Increases resting metabolic rate.
Shared Research Applications
These peptides target different research areas. Lixisenatide focuses on Metabolic Health, while Tesofensine targets Weight Loss, Appetite Suppression.
Safety Considerations
Lixisenatide: Common (>=5%): nausea (25%), vomiting (10%), headache (9%), diarrhea (8%) GI side effects are typically transient, most common during first 2-3 weeks of treatment Hypoglycemia: increased risk when combined with sulfonylureas or insulin; dose reduction of concomitant medications may be needed
Tesofensine: Phase 2 trials reported increased heart rate (5-8 bpm) and blood pressure elevation at higher doses Common side effects: dry mouth, insomnia, constipation, nausea, diarrhea Psychiatric effects reported: anxiety, mood changes (consistent with monoamine reuptake inhibitors)
Shop Research Peptides
Tesamorelin 10mg
10mg
BPC-157 5mg
5mg
Retatrutide 20mg
20mg
Retatrutide 10mg
10mg
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.